https://doi.org/10.4081/monaldi.2025.3566
Long-term colchicine therapy in acute coronary syndromes: a systematic review and meta-analysis of randomized controlled trials
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 2 December 2025
Anti-inflammatory therapy, particularly colchicine, has emerged as a potential secondary prevention strategy post-acute coronary syndrome (ACS). This meta-analysis assessed the impact of long-term colchicine therapy (≥12 months) compared to standard care on cardiovascular events in post-ACS patients. A systematic search of PubMed, Cochrane, Scopus, and Web of Science was conducted on December 22, 2024, for randomized controlled trials (RCTs) comparing long-term (≥12 months) treatment with colchicine to standard care in ACS patients. Outcomes assessed included all-cause mortality, cardiovascular death, myocardial infarction (MI), ischemia-driven revascularization, and stroke. Three RCTs (COLCOT, COPS, and CLEAR SYNERGY) with 12,602 patients were included. Colchicine did not significantly reduce all-cause mortality [hazard ratio (HR) 1.01, 95% confidence interval (CI): 0.67-1.53; I2=54%], cardiovascular death (HR 1.01, 95% CI: 0.80-1.29; I2=0%), or MI (HR 0.86, 95% CI: 0.71-1.05; I2=0%). Ischemia-driven revascularization (HR 0.61, 95% CI: 0.30-1.21; I2=81%) and stroke (HR 0.55, 95% CI: 0.18-1.64; I2=75%) showed non-significant reductions with high heterogeneity. The composite outcome of cardiovascular death, MI, revascularization, or stroke was not significantly reduced (HR 0.80, 95% CI: 0.59-1.07; I2=73%). These findings suggest that long-term colchicine therapy did not confer a consistent reduction in major cardiovascular outcomes after ACS. The pooled results indicate an overall null effect; however, the substantial heterogeneity across trials limits the certainty of this conclusion. This analysis may prompt a reassessment of colchicine’s preventive role in ACS. Future studies should aim to reduce heterogeneity through standardized protocols and follow-up reporting and to explore whether subgroups, such as patients with elevated inflammatory markers, may derive benefit.
Downloads
Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015;36:1163-70. DOI: https://doi.org/10.1093/eurheartj/ehu505
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. New N Engl J Med 2005;352:1685-95. DOI: https://doi.org/10.1056/NEJMra043430
Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9. DOI: https://doi.org/10.1056/NEJM199704033361401
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43. DOI: https://doi.org/10.1056/NEJM200003233421202
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31. DOI: https://doi.org/10.1056/NEJMoa1707914
Leung YY, Yao Hui LL, Kraus VB. Colchicine--update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 2015;45:341-50. DOI: https://doi.org/10.1016/j.semarthrit.2015.06.013
Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis 2018;269:262-71. DOI: https://doi.org/10.1016/j.atherosclerosis.2017.12.027
Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-61. Erratum in: Nature 2010;466:652. DOI: https://doi.org/10.1038/nature08938
Nidorf SM, Eikelboom JW, Thompson PL. Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease. J Cardiovasc Pharmacol Ther 2014;19:45-52. DOI: https://doi.org/10.1177/1074248413499972
Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J 2024;45:3415-537. DOI: https://doi.org/10.1093/eurheartj/ehae177
Jolly SS, d'Entremont MA, Lee SF, et al. Colchicine in acute myocardial infarction. N Engl J Med 2025;392:633-42. DOI: https://doi.org/10.1056/NEJMoa2405922
Fiolet ATL, Poorthuis MHF, Opstal TSJ, et al. Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials. eClinicalMedicine 2024;76:102835. DOI: https://doi.org/10.1016/j.eclinm.2024.102835
Shaikh S, Hamza M, Neppala S, et al. Colchicine for secondary prevention in patients with acute coronary syndrome: a systematic review and meta-analysis. Int J Cardiol 2025;425:133045. DOI: https://doi.org/10.1016/j.ijcard.2025.133045
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W64. DOI: https://doi.org/10.7326/0003-4819-151-4-200908180-00135
Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;381:2497-505. DOI: https://doi.org/10.1056/NEJMoa1912388
Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation 2020;142:1890-900. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.050771
Tong DC, Bloom JE, Quinn S, et al. Colchicine in patients with acute coronary syndrome: two-year follow-up of the Australian COPS randomized clinical trial. Circulation 2021;144:1584-6. DOI: https://doi.org/10.1161/CIRCULATIONAHA.121.054610
Fiolet ATL, Opstal TSJ, Mosterd A, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J 2021;42:2765-75. DOI: https://doi.org/10.1093/eurheartj/ehab115
Younas A, Awan Z, Khan T, et al. The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol 2025;50:102878. DOI: https://doi.org/10.1016/j.cpcardiol.2024.102878
Van Broekhoven A, Mohammadnia N, Silvis MJM, et al. End-of-trial inflammatory biomarkers, lipid levels, creatine kinase and markers of renal and liver function in the LoDoCo2 trial. Eur Heart J 2022;43:ehac544.1266. DOI: https://doi.org/10.1093/eurheartj/ehac544.1266
Stewart S, Yang KCK, Atkins K, et al. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther 2020;22:28. DOI: https://doi.org/10.1186/s13075-020-2120-7
Hemkens LG, Ewald H, Gloy VL, et al. Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis. Heart 2016;102:590-6. DOI: https://doi.org/10.1136/heartjnl-2015-308542
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61:404-10. DOI: https://doi.org/10.1016/j.jacc.2012.10.027
Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020;383:1838-47. DOI: https://doi.org/10.1056/NEJMoa2021372
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.